New Dupixent® and Itepekimab Data at ERS Showcase Innovation and Leadership in Respiratory Diseases

Regeneron Pharmaceuticals, Inc. announced that 20 abstracts featuring Dupixent® (dupilumab) and the investigational therapy itepekimab will be showcased at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria, from September 7 to 11. These abstracts, presented in partnership with Sanofi, include four oral presentations and provide new insights into treatments for chronic obstructive pulmonary disease (COPD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).

George D. Yancopoulos, M.D., Ph.D., co-Chairman, President, and Chief Scientific Officer at Regeneron, emphasized that the presentations at the ERS Congress demonstrate the company's dedication to addressing complex respiratory diseases. He highlighted the importance of their research on Dupixent and itepekimab in supporting COPD patients regardless of their smoking history.

One of the significant presentations is a pooled analysis of Phase 3 BOREAS and NOTUS trials, focusing on patients with uncontrolled COPD and type 2 inflammation. The trials showed that patients treated with Dupixent experienced a 31% reduction in the annual rate of moderate or severe COPD exacerbations over 52 weeks compared to those on placebo. This analysis formed the basis for the recent European Commission approval and other regulatory submissions for Dupixent in patients with uncontrolled COPD.

Additional research will be presented from the Phase 4 VESTIGE trial, which evaluated the effects of Dupixent on airway remodeling in adults with asthma. New data will be shared on the impact of Dupixent treatment on airway inflammation and mucus plugging at 4 weeks, as well as on clinical remission outcomes after 4 and 24 weeks of treatment.

Dupixent, developed using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling without being an immunosuppressant. Dupixent has been shown to significantly reduce type 2 inflammation in multiple Phase 3 trials and is approved in over 60 countries for various indications, including atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU), and COPD. More than 950,000 patients worldwide are currently receiving Dupixent treatment.

Regeneron and Sanofi are also exploring the potential of dupilumab in treating other type 2 inflammation-driven diseases, such as chronic pruritus of unknown origin and bullous pemphigoid, through ongoing Phase 3 trials.

Itepekimab, another investigational therapy developed with VelocImmune technology, is a fully human monoclonal antibody that targets interleukin-33 (IL-33), a key factor in airway inflammation. It is currently undergoing clinical investigation in two COPD Phase 3 trials.

Regeneron's VelocImmune technology leverages a genetically engineered mouse platform with a humanized immune system to produce optimized fully human antibodies. This technology has been instrumental in creating several FDA-approved antibodies, including REGEN-COV® (casirivimab and imdevimab), Dupixent, Libtayo® (cemiplimab-rwlc), and others.

As a leading biotechnology company, Regeneron is dedicated to developing transformative medicines for serious diseases. Their proprietary technologies, including VelociSuite®, enable the production of fully human antibodies and bispecific antibodies. The company is also advancing the frontier of medicine with data-driven insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms to identify innovative targets for treating or curing diseases.